Inhibition of Rho Kinase Regulates Specification of Early Differentiation Events in P19 Embryonal Carcinoma Stem Cells by Krawetz, Roman J. et al.
Inhibition of Rho Kinase Regulates Specification of Early
Differentiation Events in P19 Embryonal Carcinoma Stem
Cells
Roman J. Krawetz
1*, Jaymi Taiani
3, Alexis Greene
2, Gregory M. Kelly
4, Derrick E. Rancourt
2
1Department of Surgery, University of Calgary, Calgary, Canada, 2Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, Canada,
3Department of Medical Science, Faculty of Medicine, University of Calgary, Calgary, Canada, 4Molecular Genetics Unit, Department of Biology, University of Western
Ontario, London, Canada
Abstract
Background: The Rho kinase pathway plays a key role in many early cell/tissue determination events that take place in
embryogenesis. Rho and its downstream effector Rho kinase (ROCK) play pivotal roles in cell migration, apoptosis
(membrane blebbing), cell proliferation/cell cycle, cell-cell adhesion and gene regulation. We and others have previously
demonstrated that inhibition of ROCK blocks endoderm differentiation in embryonal carcinoma stem cells, however, the
effect of ROCK inhibition on mesoderm and ectoderm specification has not been fully examined. In this study, the role of
ROCK within the specification and differentiation of all three germ layers was examined.
Methodology/Principal Findings: P19 cells were treated with the specific ROCK inhibitor Y-27623, and increase in
differentiation efficiency into neuro-ectodermal and mesodermal lineages was observed. However, as expected a dramatic
decrease in early endodermal markers was observed when ROCK was inhibited. Interestingly, within these ROCK-inhibited
RA treated cultures, increased levels of mesodermal or ectodermal markers were not observed, instead it was found that the
pluripotent markers SSEA-1 and Oct-4 remained up-regulated similar to that seen in undifferentiated cultures. Using
standard and widely accepted methods for reproducible P19 differentiation into all three germ layers, an enhancement of
mesoderm and ectoderm differentiation with a concurrent loss of endoderm lineage specification was observed with Y-
27632 treatment. Evidence would suggest that this effect is in part mediated through TGF-b and SMAD signaling as ROCK-
inhibited cells displayed aberrant SMAD activation and did not return to a ‘ground’ state after the inhibition had been
removed.
Conclusions/Significance: Given this data and the fact that only a partial rescue of normal differentiation capacity occurred
when ROCK inhibition was alleviated, the effect of ROCK inhibition on the differentiation capacity of pluripotent cell
populations should be further examined to elucidate the role of the Rho-ROCK pathway in early cellular ‘fate’ decision
making processes.
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Introduction
Rho proteins, which include Rho, Rac1, and Cdc42, control
numerous cellular processes, such as cell adhesion, motility, prolifer-
ation, differentiation, and apoptosis [1–4]. One of the most well-
defined effectors of Rho is the Rho-associated coiled-coil-containing
protein kinase (ROCK). The ROCK inhibitor Y-27632 has recently
attracted the attention of stem cell researchers as this molecule
enhances the survival of human embryonic stem (hES) cells during
dissociation [5]. Y-27632 inhibits ROCK by competing with its ATP
binding site [6]. This in turn affects signal transduction in the Rho
pathway, which perturbs downstream effects including the regulation
of cytoskeletal integrity, cell adhesion and gene transcription [1–4,7].
In the current study we used the P19 teratocarcinoma cell line
as a model system to study the effects of ROCK inhibition on
multi-lineage differentiation capability. P19 cells were derived
from an embryonal carcinoma (EC) that was induced in a C3H/
He strain mouse over 20 years ago [8]. These cells are pluripotent
and thus possess the ability to differentiate into cells from all three
germ layers [9–11]. Like other EC cells, P19 cells appear to
differentiate using the same mechanisms as normal embryonic
stem cells and will contribute to normal embryonic development
when injected into mouse embryos [12]. Reproducible and
validated differentiation protocols are established for P19 cells
and these methods have had widespread usage with highly
reproducible results [12]. For example, exposure to retinoic acid
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differentiation into neuronal and glial cells [13]. Also, endoderm
derivatives are generated from P19 cells when they are treated
with RA [12], whereas aggregates of P19 cells differentiate into
cardiac and skeletal muscle in the presence of dimethyl sulfoxide
(DMSO) [12]. This ability to develop into a disparate number of
cell types therefore places the P19 cell line in a favourable position
to study the role of RhoA in the differentiation process(es).
We and others have demonstrated that endoderm differentia-
tion of mouse P19 and F9 EC cells requires the activation of Ga13
and Rho [14–18]. However, the role of ROCK within early cell
fate decisions to mesoderm and endoderm has not been
elucidated. To address this, the effects of blocking ROCK activity
using the Y-27632 inhibitor were assessed on the ability of P19
cells to differentiate into specialized cell types from all three germ
layers. Overall, it was observed that inhibition of ROCK activity
by specific inhibitors altered the differentiation potential of
pluripotent cells. In particular, this inhibition promoted P19 cell
differentiation into mesodermal and ectodermal fates while
reducing endodermal differentiation. Furthermore, Y-27632
treatment during directed differentiation into endodermal lineages
resulted in an up-regulation of pluripotent markers with no
indication of spontaneous differentiation into other lineages.
Results
Retinoic acid induced differentiation is inhibited by Y-
27632
Endodermal differentiation using a static monolayer culture of
P19 cells, and ectodermal and mesodermal differentiation with
suspended aggregates of P19 cells was carried out as described
previously [11–15]. To assess the effect of ROCK inhibition on
differentiation, P19 cells were treated with the ROCK inhibitor Y-
27632 and then induced to form endoderm or mesoderm and
ectoderm.
Extraembryonic primitive endoderm formation, induced in P19
cultures with the addition of RA, was accompanied by an increase
in GATA-6 gene expression (Figure 1A). However, when Y-27632
was added to RA-treated cultures, GATA-6 expression was similar
to that observed in the Y-27632-treated, undifferentiated cultures
(Figure 1A). Interestingly, when P19 cells were pre-treated with Y-
27632 for 4 days and then allowed to recover, GATA-6 expression
increased, but did not recover to the same levels seen in untreated
cells. Immunofluorescence analysis was also used to identify
markers of differentiation in untreated and Y-27632-treated cells
(Figure 1B–E). Undifferentiated P19 cells did not express GATA-6
(Figure 1B), whereas those exposed to RA showed GATA-6
staining in the nucleus (Figure 1C). Nuclear GATA-6 expression
was not observed in RA and Y27632-treated cells (Figure 1D), but
was present in RA-treated cells following the removal of the
ROCK inhibitor (Figure 1E). The intensity of staining, however,
was not to the extent as that observed in the controls. The
expression of Troma-1, a marker of primitive endoderm, was also
examined using qPCR (Figure 1F). Like GATA-6 gene expression,
Troma-1 mRNA levels were significantly decreased in RA-
induced endodermal cultures treated with Y-27632 relative to
cells treated with RA alone. A partial rescue in Troma-1
expression also occurred when cells were allowed to recover from
the inhibitor before being exposed to RA (Figure 1F). As expected,
Troma-1 staining was weak in undifferentiated P19 aggregates
(Figure 1G), whereas RA treatment induced prominent staining
(Figure 1H). As with GATA-6, Troma-1 staining following Y-
27632 treatment (Figure 1I) was similar to that in undifferentiated
cells. Following the removal of the inhibitor, the reappearance of
few Troma-1-positive filaments in RA-induced cells paralleled that
seen for GATA-6 (Figure 1J). Finally, cells were dissociated and
FACS analysis was used to identify the number of cells expressing
either GATA-6 or Troma-1 (Figure 1K). RA treatment resulted in
approximately 80% of the cells being positive for GATA-6 or
Troma-1, whereas this number dropped to 12–15% when the
ROCK inhibitor was present. Removing the inhibitor and
allowing the cells to recover before endodermal induction resulted
in approximately 65% of the cells being positive for GATA-6 and
Troma-1 (Figure 1K). This data thereby corroborates the results
seen from the two other independent analyses. That no significant
difference in the mRNA level of GATA-6 or Troma-1 in cultures
where ectodermal or mesodermal differentiation was induced by
RA+LIF or DMSO, respectively, demonstrates the specificity of
the differentiation protocol (Figure 1A,F). Together, these results
would suggest that RhoA activity in P19 cells is required for
endodermal differentiation.
Differentiation of P19 into mesoderm or neural-ectoderm
is enhanced by ROCK inhibition
Mesodermal differentiation of P19 cells was induced using
DMSO. When P19 cell aggregates were exposed to DMSO,
mRNA levels of the mesoderm-specific transcription factor
Brachyury increased dramatically as did smooth muscle Actin
(SMA) and MyoD (Figure 2A). The relative levels of Brachyury,
after pre-treatment with Y-27632 and removal of the inhibitor,
were not significantly different from control DMSO-treated cells
(Figure 2A), and no obvious Brachyury staining was found in
undifferentiated P19 cells (Figure 2B). The induction of mesoderm
was accompanied by the appearance of Brachyury in the nuclei of
a sub-population of cells (Figure 2C), whereas when cells were
treated with DMSO in the presence of Y-27632, almost every cell
exhibited nuclear Brachyury staining (Figure 2D). Brachyury-
positive cells were also observed in those pre-treated with Y-27632
and then with DMSO (Figure 2E). This staining pattern was
similar to that in the DMSO-treated cells.
The muscle markers SMA and MyoD were also examined and
their patterns of expression compared to that for Brachyury. SMA
actin mRNA levels were significantly up-regulated following Y-
2632 treatment (Figure 2F). No actin fibres were observed in
undifferentiated cells (Figure 2G), however, multiple actin fibres
were seen following DMSO induction (Figure 2H). When Y-27632
and DMSO were added together, SMA fibres formed and the
nuclei appeared larger (Figure 2I). Pre-treatment with Y-27632
followed by DMSO produced similar results (Figure 2J). Quan-
titative PCR analysis revealed that a significant up-regulation in
MyoD mRNA levels was observed following DMSO treatment
(Figure 2K). At the protein level, MyoD was not detected in
undifferentiated P19 cells (Figure 2L), but was seen in the
cytoplasm and nucleus of cells induced with DMSO (Figure 2M).
It is interesting to note that MyoD was observed exclusively in the
nuclei of cells that were exposed to Y-27632 while in the induction
media (Figure 2N). The pattern of MyoD staining in pre-treated
cells (Figure 2O) was similar to that in cells treated with DMSO
alone. Finally, FACS analysis of cells stained for Brachyury, SMA
or MyoD revealed an interesting trend. Results showed that for
each of the markers, those cells exposed to DMSO and Y-27632
demonstrated a higher percentage of positive staining compared to
DMSO alone or Y-27632-pre-treated cells (Figure 2P).
To better understand if ROCK has a role in early ectodermal
differentiation, P19 cell aggregates were exposed to RA & LIF to
block endodermal and mesodermal differentiation [15]. Glial
fibrillary acidic protein (GFAP) and NF-68 were used as markers
of neuro-ectodermal differentiation. Quantitative PCR results
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tiated cultures, increased in cells following exposure to RA+LIF
(Figure 3A). Moreover, these levels increased when the RA+LIF
treatment was combined with Y-27632 (Figure 3A). Immunoflu-
orescence microscopy was also used to identify changes in protein
expression. Results did not show any obvious GFAP staining in
Figure 2. Differentiation of P19 cells into mesoderm is enhanced by Y-27632 treatment. P19 aggregates were treated with 1% DMSO to
induce differentiation into mesoderm. Total mRNA was collected and probed with Brachyury, an early mesodermal marker. P19 cells treated with
DMSO displayed an increase in Brachyury expression compared to cells treated with Y-27632 (A). Immunofluorescence analysis of cells either
undifferentiated (B) or treated with DMSO treated (C) DMSO+Y-27632 treated (D) or DMSO treatment with Y-27632 pre-treatment (E) showing
Brachyury localized to the nucleus. qPCR results for SMA show expression levels had increased following DMSO+Y-27632 treatment (F).
Immunofluorescence of SMA in undifferentiated (G) DMSO treated (H) DMSO+Y-27632 treated (I) or DMSO treatment with Y-27632 pre-treatment (J).
MyoD mRNA expression also increased with Y-27632 treatment in the presence of DMSO (K). Immunofluorescence of MyoD in undifferentiated cells
(L) and in those treated with DMSO (M) DMSO+Y-27632 treated (N) or DMSO with Y-27632 pre-treatment (O). FACS analysis demonstrates a
significant increase in Brachyury, SMA and MyoD positive cells with Y-27632 treatment (P). Scale bar equals 50 mm, green staining represents the
primary antibody, and blue staining is the nuclear dye TOTO-3. * Significance accepted at p,0.05.
doi:10.1371/journal.pone.0026484.g002
Figure 1. Y-27632 treatment of P19 cells inhibits the differentiation of primitive endoderm. Monolayer grown P19 cells induced to
differentiate with RA were collected for mRNA quantification and immunofluorescence. Total mRNA from all treatment groups was probed with a
GATA-6 primer/probe, which is a marker of primitive endoderm. The RA treatment group displayed an increase of GATA-6, but decreased when RA
was supplemented with Y-27632, with moderate recovery when cells where induced to differentiate after Y-27632 pre-treatment and removal of the
inhibitor (A). Immunofluorescence of GATA-6 in undifferentiated cells (B) and in RA treated (C), RA+Y-27632 treated (D) or RA+Y-27632 pre-treated
cells. Total mRNA converted to cDNA and probed with Troma-1, showed a dramatic decrease in expression when Y-27632 was present either during
or before differentiation (F). Immunofluorescence of Troma-1 in undifferentiated (B) RA treated (C), RA+Y-27632 treated (D) and RA+Y-27632 pre-
treated cells. FACS analysis demonstrates a significant decrease in GATA-6 and Troma-1 positive cells with Y-27632 present (K). Scale bars equals
50 mm, green staining represents the primary antibody, and blue staining is the nuclear dye TOTO-3. * Significance accepted at p,0.05.
doi:10.1371/journal.pone.0026484.g001
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ectoderm differentiation. Total mRNA was collected, converted to cDNA and used in a PCR to examine GFAP expression, a marker of ectodermal
derived neural cell types (A). GFAP levels increased with RA+LIF treatment in the presence or absence of Y-27632. Increased GFAP expression was also
detected in the DMSO treated groups supplemented with Y-27632. Immunofluorescent detection of GFAP in undifferentiated (B) RA+LIF (C) RA+LIF
and Y-27632 (D) or RA+LIF with Y-27632 pre-treated cells (E). qPCR with NF-68 primers showed an increase in expression in cells exposed to Y-27632
during differentiation (F). Immunofluorescent detection of NF-68 in undifferentiated cells or those exposed to the following: (G) RA+LIF (H) RA+LIF
and Y-27632 (I) or RA+LIF with Y-27632 pre-treatment (J). FACS analysis demonstrates increased numbers of GFAP- (trend) and NF-68-positive cells
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positive cells were present at the periphery of the aggregates when
cells were exposed to RA+LIF (Figure 3C). Dramatic morpholog-
ical changes to these ectodermal cells occurred when they were
treated with Y-27632 (Figure 3D). The most obvious changes
included the appearance of more GFAP-positive cells, the absence
of cell aggregates and the change in individual cell morphology.
The fact that these changes were maintained when the inhibitor
was removed (Figure 3E), suggested that attenuating Rho activity
augmented the signaling required by cells to adopt an ectodermal
fate.
Immunofluorescence using an antibody against NF-68, which
recognizes neuro-filaments, was used to further test this hypothesis
that blocking Rho activity influenced the decision of cells to form
neuro-ectoderm. Results show that NF-68 mRNA levels increased
in cells treated with RA+LIF and these levels were significantly
higher when cultures were exposed to Y-27632 (Figure 3F).
Immunofluorescence data showing extensive NF-68 staining in
RA+LIF-treated P19 cells (Figure 3H), but not in undifferentiated
cells (Figure 3G) corroborates the qPCR analysis. Likewise, NF-68
staining was even more prominent in ectodermal cells exposed to
the ROCK inhibitor (Figure 3I), and this trend in staining seen
using the other markers was once again maintained when the
inhibitor was removed (Figure 3J). Finally, data from FACS
analysis of GFAP and NF-68 positive cells were consistent with the
mRNA and immunofluorescence data (Figure 3K). The number of
GFAP (although not significantly) and NF-68 positive cells
increased when differentiated cells were exposed to Y-27632,
however, the relative percent of each declined if the inhibitor was
removed and the cells had time to recover before the induction of
differentiation (Figure 3K).
Signal transduction and pluripotency is regulated by
ROCK
Data would indicate that blocking ROCK activity negatively
affects P19 cells from differentiating into endoderm, positively
affects the differentiation towards mesodermal and ectodermal
lineages, or a combination of both. The next series of experiments
were designed to investigate whether or not blocking ROCK
activity affects pluripotency of these EC cells. Oct-4 and SSEA-1
are markers of pluripotency and their expression was examined in
undifferentiated and differentiated P19 cultures. Quantitative
PCR analysis confirmed that differentiation into endoderm,
ectoderm or mesoderm triggered a decrease in Oct-4 and
SSEA-1 expression compared to that in undifferentiated cultures
(Figure 4A,F). Furthermore, the addition or pre-treatment with Y-
27632 had no affect on the declining Oct-4 and SSEA-1 levels
seen in cells induced to form ectoderm (RA+LIF) or mesoderm
(DMSO) (Figure 4A,F). Interestingly, Oct-4 and SSEA-1 levels
remained elevated when cells were treated with RA in the
presence of Y-27632 (Figure 4A,F). In contrast, however, cells pre-
treated with the inhibitor and allowed to recover did not show this
trend and Oct-4 and SSEA-1 levels remained low. When the
localization of Oct-4 was examined by immunofluorescence
microscopy, staining was seen in the nuclei of untreated cells
(Figure 4B), but absent when the cells differentiated into endoderm
(Figure 4C). RA induced cultures treated with Y-27632 showed
obvious Oct-4 staining throughout the cell and this was
accompanied by dramatic changes in cellular morphology
(Figure 4D). Y-27632 pre-treated cells allowed to recover, before
being induced with RA, exhibited similar changes in cell
morphology, but Oct-4 staining was weak (Figure 4E).
SSEA-1 expression showed a similar trend as observed for Oct-
4. Positive staining was seen on differentiated P19 cells (Figure 4G),
but absent on those induced with RA (Figure 4H). SSEA-1 was
also expressed on RA-induced cells treated with Y-27632
(Figure 5I), and like Oct-4, staining was still visible, albeit weak,
on cells pre-treated with the inhibitor and then induced with RA
(Figure 4J). FACS analysis corroborated the immunofluorescence
data suggesting that pluripotency was enhanced when Rho
signaling was attenuated (Figure 4K). Results showed few Oct-4
and SSEA-1-positive cells when endoderm was induced, whereas
the majority of cells were positive for both markers when the
ROCK inhibitor was present, or after it was removed (Figure 4K).
Together, these results would support the notion that Rho activity
is required for cells to adopt an endodermal lineage because it lifts
the restrictions required to keep cells in a pluripotent state.
To help elucidate the mechanism(s) behind these observations,
attention turned to signal transduction pathways involved in
regulation of both pluripotency and differentiation. b-catenin is
involved in the patterning of all three germ layers during early
mouse development and it participates in numerous pathways
required for the regulation of differentiation. Recent studies in
human embryonic stem cells have demonstrated that ROCK
inhibition blocks cadherin proteins from undergoing ‘membrane
flipping’ [19]. This flipping normally releases b-catenin from the
plasma membrane and allows it to translocate into the nucleus.
Furthermore, we have also shown that nuclear translocation of b-
catenin accompanies F9 endodermal differentiation [14]. To
extend these studies, the levels of b-catenin mRNA expression
were examined in differentiating P19 cells in the presence or
absence of Y-27632. Results show that levels were comparable
between undifferentiated P19 cultures and those treated with
DMSO or RA+LIF (Figure 5A). There was, however, a statistically
significant increase in b-catenin levels during RA-induced
differentiation (Figure 5A), which was expected given our previous
report [14]. Although b-catenin levels in RA-induced cells were
negatively affected by Y-27632 treatment (Figure 5A), they were
still higher than those in untreated, undifferentiated cells. The
opposite, however, was seen in cells induced with DMSO or
RA+LIF in the presence of Y-27632, where the levels were
significantly lower than those in the controls. It is noteworthy that
this decrease was not as dramatic in cells pre-treated with the
inhibitor and then induced towards a specific lineage. Having
determined that b-catenin levels were influenced either directly or
indirectly by ROCK activity, the focus turned to the sub-cellular
distribution of b-catenin since the targets of b-catenin signaling are
not only influenced by the level of b-catenin expression, but also
by the localization of this protein [14,16–18]. We and others have
demonstrated that b-catenin translocation to the nucleus accom-
panies the differentiation of F9 cells into primitive endoderm
under RA treatment and although b-catenin is expressed in
undifferentiated F9 cells, it is found primarily at the plasma
membrane [14,16–18]. Immunofluorescence microscopy revealed
that b-catenin was also expressed at the plasma membrane of
undifferentiated P19 cells (Figure 5B). Similarly, b-catenin
translocated into the nucleus when P19 cells were induced to
form endoderm, (Figure 5C). In RA treated P19 cells Y-27632
blocked the nuclear translocation of b-catenin, and staining was
with Y-27632 treatment during RA+LIF induced differentiation (K). Scale bar equals 50 mm, green staining represents the primary antibody, and blue
staining is the nuclear dye TOTO-3. * Significance accepted at p,0.05.
doi:10.1371/journal.pone.0026484.g003
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pluripotency. Total mRNA collected from samples was used in a qPCR with primers against the pluripotency marker Oct-4 (A). As expected, during
directed differentiation into all three germ layers, the expression of Oct-4 is decreased. However, under RA+Y-27632 treatment (A) Oct-4 levels are
more similar to that in undifferentiated cells. Immunofluorescent detection of Oct-4 in undifferentiated cells (B) and in cells treated with RA (C) RA
plus Y-27632 (D) or RA with Y-27632 pre-treatment (E). qPCR with SSEA-1 probes showed similar levels and trends to that of Oct-4, with significant
decreases observed during differentiation into any lineage (F). Furthermore, as with Oct-4 SSEA-1 mRNA expression remained at control levels during
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were allowed to recover from ROCK inhibition, then treated with
RA, b-catenin staining was seen in the nucleus (Figure 5E).
Together, the results would suggest that blocking Rho activity
promoted pluripotency, but alleviating this block thereby facili-
tating the translocation of b-catenin to the nucleus, promotes
differentiation towards the endodermal lineage.
Having identified a requirement for Rho activity and canonical
b-catenin signaling during differentiation of P19 cells towards
specific lineages, the last pathway we considered was that involving
TGF-b. The TGF-b pathway is involved in cellular differentiation
and in the maintenance of stem cell pluripotency through the
regulation of Nanog and Oct-4 expression [20,21]. In some cases
TGF-b signals directly through Rho and ROCK, and inhibition of
ROCK blocks the effects observed when TGF-b is added to the
system [22,23]. Involvement of the TGF-b pathway was explored
by probing cell lysates for phosphorylated SMAD2/3, whose
presence would be indicative of active TGF-b signaling (Figure 5F).
Immunoblot analysis showed that the levels of active p-SMAD 2/3
increased with RA treatment, but surprisingly, the levels in cells
treated with RA and Y-27632 were similar to those in the controls
(Figure 5F). Furthermore, when cells were first treated with the
inhibitor and then given time to recover, p-SMAD 2/3 levels did
not increase, but instead they remained comparable to the controls
(Figure 5F). This data would indicate that ROCK may play a role
in the activation of SMAD 2/3 independent of TGF-b.
Having shown that Rho signaling acting through ROCK
influences two signaling pathways involved in P19 differentiation,
the next logical question was to investigate the effectors downstream
of this ROCK activity. ROCK is known to act on numerous
substrates including the members of the ERM (Ezrin, Radixin and
Moesin) protein family [24]. Our previous studies with F9 cells have
shown that Moesin is essential for both extraembryonic endodermal
differentiation and survival [14], which leads us to propose that a
similar requirement may exist for P19 cells. To address this, the
expression profile of Moesin mRNA as well as the sub-cellular
localization of the protein was examined in P19 cells treated with
RA in the presence or absence of Y-27632. Results show that
Moesin mRNA levels increased significantly during RA induction
(Figure 5G), but surprisingly this expression was inhibited in cells
exposed to Y-27632. In untreated cells immunofluorescent analysis
with a pan-ERM antibody revealed a relatively homogenous
cytoplasmic staining pattern with some foci present within the
colonies (Figure 5H). Although cells treated with RA still showed
these positive foci as well as staining at the cell membrane, staining
could also be seen within nuclei, which we reported previously for
F9 cells [20] (Figure 5I). Significantly, the addition of Y-27632
blocked this nuclear staining even though positive signals were still
seen in the cytoplasm (Figure 5J). Pre-treating cells with Y-27632
before RA induction resulted in cells having both staining patterns
(Figure 5K). Together, these results would suggest that the Moesin
redistribution to the nucleus in RA-treated P19 cells was not unlike
that seen in F9 cells, and that this re-localization is dependent on
ROCK activity. The necessity of Moesin for extraembryonic
endoderm differentiation remains to be determined, but it is easy to
envisage a model whereby ROCK activity not only facilitates the
phosphorylation and subsequent translocation of Moesin to the
nucleus, but in parallel this activity is required to negatively regulate
the TGF-b signaling required to keep ES cells pluripotent
(Figure 5L).
Discussion
Induced differentiation of P19 cells has been characterized
extensively and it is well known that in the absence of chemical
inducers, these cells rarely differentiate spontaneously [12]. In
contrast, exposure of P19 cells to RA leads to formation of
endodermal cells [9–11]. Likewise, neuro-ectodermal lineages,
including neurons and astroglial cells, are generated when P19
cells are aggregated and then exposed to RA and LIF [9–12].
Finally, mesodermal lineages, including cardiac and skeletal muscle,
are formed when P19 aggregates are treated with DMSO.
Interestingly, however, is that aggregation of P19 cells in the
absence of chemical inducers results in the differentiation of the cells
into predominantly endodermal lineages, signifying that cell-matrix
interactions maintains the P19 cells in an undifferentiated state (in
the absence of inducers), whereas cell-cell contact without cell-
matrix interactions can in part substitute for RA [9]. Under all of
these conditions, LIF inhibits differentiation of P19 cells towards
endodermal or mesodermal lineages, but does not inhibit
differentiation of neuro-ectodermal lineages. Thus, treatment with
this cytokine contributes to a higher efficiency of ectodermal
differentiation when P19 cells are concurrently treated with high
doses of RA [13]. Cell aggregation is essential for P19 cell neural
differentiation, while over-expression of RA-induced genes triggers
P19cellneuraldifferentiationfromwithinthese aggregates [25–27].
We and others have demonstrated the necessity of cell-cell/cell-
matrix adhesion for the proper maintenance and differentiation of
stem cells [28,29]. Furthermore, the extensive intracellular
remodelling that takes place during differentiation is accompanied
by extensive changes in gene expression. Rho-associated protein
kinases (ROCKs) are downstream effectors of Rho GTPase, which
function in numerous physiological processes including the
reorganization of cytoskeletal elements [30–32]. In addition to
this role, our results would indicate that ROCK inhibition blocks
the differentiation of endoderm, whereas it also attenuates the
induction of P19 cells into mesoderm or ectoderm, but only in the
presence of DMSO or RA and LIF, respectively. If the ROCK
inhibitor is directly affecting endoderm differentiation by interfer-
ing with RA-induced gene regulation, we would expect both
endoderm and ectoderm differentiation to be affected by Y-27632
since they both rely on being triggered by RA. However, this is not
the case, as RA and LIF in conjunction with ROCK inhibition
leads to an increase in GFAP and NF-68 expression, implying that
ROCK itself must be instrumental only in endoderm differenti-
ation of P19 EC cells.
Restriction of endodermal differentiation through ROCK
inhibition may result from altered signaling through the ERM
proteins, which are regulated by ROCK. Normally, under Rho
activation, ROCK phosphorylates the ERM proteins and this
leads to remodelling of the actin cytoskeleton [33]. We have
previously demonstrated that the over-expression of Moesin
influences EC cells to differentiate into primitive endoderm in
the absence of chemical inducers [34]. In the present study, we
have demonstrated that Moesin mRNA levels are up-regulated
during RA induced differentiation, and Y-27632 treatment
RA with Y-27632 treatment (F). Immunofluorescent detection of SSEA-1 in undifferentiated cells (G) and in those treated with RA (H) RA with Y-27632
(I) or RA with Y-27632 pre-treatment (J). FACS analysis demonstrates increased numbers of Oct-4 and SSEA-1 positive cells during RA induced
differentiation and Y-27632 treatment (K). Scale bar equals 50 mm, green staining represents the primary antibody, and blue staining is the nuclear
dye TOTO-3. * Significance accepted at p,0.05.
doi:10.1371/journal.pone.0026484.g004
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specifically neuro-ectoderm differentiation through RA treatment
may activate signaling pathways that diverge somewhere before
the level of Rho and ROCK. As such, the capacity of P19 cells to
differentiate into ectodermal lineages would not be affected by
ROCK inhibition, supporting our observations in the current
study. Alternatively, ROCK may be functioning within a model by
which multiple signal transduction pathways are not only
responsible for the maintenance of pluripotency, but are also
essential for differentiation into specific cell types of all three germ
layers. In this case, where pluripotency vs. differentiation is
controlled by the same or similar factors, one would expect that a
strict balance must be maintained between numerous signals. As
an example, the literature shows that Rho and ROCK participate
with the b-catenin and TGF-b signaling pathways, even though
the TGF-b or Wnt proteins are absent [35–36]. In other cases
ROCK acts downstream when Wnt and TGF-b are present [37].
Therefore, we suggest that ROCK has the ability to serve as an
intermediate between these pathways, possibly controlling this
balance between active/inactive downstream states (Figure 5L).
This may either be direct, as ROCK inhibition can lead to the loss
of SMAD phosphorylation [22], or indirect, in the case of ROCK
stabilizing b-catenin within the cadherin complex [19].
It is also important to recognize that the Rho-ROCK pathway
is essential for maintenance and re-organization of actin stress
fibers and focal contacts, which can result in changes in cell
motility and morphology [31]. These changes are of importance as
cell-cell and cell-ECM interactions are fundamental processes
involved in cell migration, differentiation and tissue remodelling.
Not surprisingly, the inhibition of Rho or ROCK leads to a
decrease in cell-cell interactions and increased migration [31]. In
relation to this study, one would expect that decreased cell-cell
interactions during aggregate formation would impede ectoderm
differentiation [38], however, the opposite effect was observed.
Aggregation of P19 cells in the presence of Y-27632 did not
completely abolish cell adhesion, but the aggregates did not appear
as ‘tightly’ packed as in controls (data not shown). While previous
studies have demonstrated that cell-cell interactions are essential
for differentiation into ectoderm [38], we observed increased
expression of ectodermal and mesodermal markers when ROCK
is inhibited. One explanation may be that cells exhibiting a
decreased level of cell adhesion, but remaining in a three
dimensional structure may be the optimal condition for P19
ectodermal or mesodermal differentiation, possibly through
something as simple as increased diffusion of inducing factors.
Interestingly, a similar effect was not seen for endodermal
differentiation. The differentiation of primitive endoderm, de-
scribed as the earliest epithelial-to-mesenchymal transition in the
developing mouse embryo, requires an increase in migration and
decrease in cell-cell adhesion to occur under normal conditions
[39]. In some cases increased migration and decreased adhesion
have been directly observed under Y-27632 treatment [40],
however, differentiation of endoderm is not solely dependent on
these changes. In fact, Y-27632 treatment of P19 cells completely
abolished the endoderm inducing effect of RA. As we and other
groups have described, the differentiation of EC into endoderm in
a multi-factorial process that not only involves crosstalk between
signal transduction pathways, but also the modification of the
cytoskeleton [14–18,34]. We therefore suggest that ROCK is
playing many roles within the cell and that by inhibiting ROCK,
certain elements of differentiation are enhanced. At the same time
other aspects of differentiation may have a high requirement for
activation of the Rho-ROCK signaling axis, which of course
would have negative consequences when ROCK is inhibited.
Overall, we have demonstrated that ROCK is playing a role in
early fate determination of stem cells. Furthermore, it appears that
ROCK may be acting through SMAD proteins to affect changes in
gene expression in conjunction with other signal transduction
pathways (canonical Wnt signaling) to determine which fate (ecto/
endo/mesoderm) an unspecified cell will adopt. ROCK interacting
with SMADs and other pathways was reported previously [22].
Given the recent reports to indicate that ROCK inhibition has
significant effects on the differentiation of human embryonic stem
cells [41,42], our data would suggest that ROCK itself may act as a
lynch-pin in early fate determination in pluripotent stem cells.
Materials and Methods
Cell Culture
Mouse P19 cells (ATCC) were plated on 0.1% gelatin coated
35 mm dishes for protein isolation or coverslips for immunoflu-
orescence, and grown at 37uC and 5% CO2 in Dulbecco’s
Modified Eagle’s Medium (DMEM/F-12; Invitrogen) supplement-
ed with 10% fetal bovine serum (FBS; Invitrogen), 1% non-
essential amino acids (Invitrogen), b-mercaptoethanol (Invitrogen)
and 1% penicillin-streptomycin (Invitrogen). To induce differen-
tiation, aggregates containing approx. 1000 cells were formed
using the hanging drop method. Aggregates were harvested after
24 hours and replated in medium supplemented with either
10
27 M retinoic acid (RA, all-trans; Sigma) plus 1000units/ml of
LIF (Calbiochem) for ectoderm differentiation or 1% DMSO
(Sigma) for mesoderm differentiation. For endoderm differentia-
tion, cells in monolayer were treated with 10
27 M RA. Cells were
cultured in differentiation medium for 4 days before being
harvested for analysis. All treatments were carried out in the
presence or absence of 10 mM ROCK inhibitor Y-27632 (Sigma).
For Y-27632 experiments cells were cultured in the presence of
10 mM of the inhibitor for 4 days and then the inhibitor was
replaced with fresh media for an additional 4 days before
differentiation was induced. All experiments were carried out at
least 3 times using similar passage P19 cells (passages 6–10).
Protein Analysis
At the end of each experiment cells were lysed in sodium
dodecyl sulfate loading buffer containing phenylmethylsulfonyl
fluoride (PMSF; Sigma). Extracts were collected and centrifuged at
15,0006 g for 15 min at room temperature and supernatants
stored at 220uC. Protein concentration was quantified using the
Figure 5. Y-27632 mediated signal transduction during differentiation. Total mRNA collected from all groups was converted to cDNA and
probed to assay levels of b-catenin (A). b-catenin levels increased under all differentiation induction conditions, however, levels decreased
significantly when Y-27632 was added during mesodermal and ectodermal differentiation. Immunofluorescent detection of b-catenin in
undifferentiated cells (B) and cells treated with RA (C) RA plus Y-27632 (D) or RA with Y-27632 pre-treatment (E). To assay the activity of the TGF-b
pathway, cell lysates were probed with a phospo-SMAD2/3 antibody (F). Results demonstrate that a significant decrease in SMAD activation occurred
when Y-27632 was present or after pre-treatment and removal of the inhibitor. cDNA from RA induced cells was assayed for Ezrin, Radixin and Moesin
expression levels (G). A pan-ERM antibody was used to stain undifferentiated cells (H) and those exposed to RA (I) RA plus Y-27632 (J) or RA with Y-
27632 pre-treatment (K). Model representing ROCK interaction with multiple pathways influencing the ‘fate’ of unspecified stem cells (L). Scale bar
equals 50 mm, green staining represents the primary antibody, and blue staining is the nuclear dye TOTO-3. * Significance accepted at p,0.05.
doi:10.1371/journal.pone.0026484.g005
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polyacrylamide gel. The gel was then transferred to nitro-cellulose
membrane. The membrane was blocked with 3% skim milk
powder in Tris-buffered saline (TBS) for 1 hr at room tempera-
ture. After blocking, the membrane was probed for 2 hr at room
temperature with the following antibodies: GAPDH (Santa Cruz),
p-SMAD 2/3 (Santa Cruz), all using a 1:2000 dilution in Tris
buffer saline containing Tween 20 (0.5%) (TBST) and supple-
mented with skim milk powder (3%). The membrane was then
washed three times in TBST and blocked for 1 hr in 3% skim milk
powder in TBST. The corresponding secondary antibody
conjugated to an infra-red emitter (LI-COR) was added to fresh
blocking solution and incubated with the membrane for 2 hr at
room temperature. The membrane was washed three times in
TBST and scanned with the Odyssey infra-red system (LI-COR).
Statistical analysis
Statistical analysis was performed using GraphPad Prisim (v. 4)
software utilizing a 1-way ANOVA and a Bonferroni post test.
Immunofluorescence
Cells grown on coverslips were fixed in phosphate buffered
saline (PBS) containing 4% paraformaldehyde, then washed in
PBS and permeabilized with 0.1% Triton X-100 for 10 min. After
washing in PBS, cells were incubated for 20 min in 3% bovine
serum albumin (BSA) to reduce non-specific protein-protein
interactions. Cells were incubated at 37uC for 1 hr in the
appropriate primary antibody at dilutions of 1:50 in 3% BSA
[GFAP (NEB), b-catenin (DSHB), GATA-6 (Santa Cruz), SSEA-1
(DSHB), Brachyury (Santa Cruz), NF-68 (Santa Cruz), p-SMAD
2/3 (Santa Cruz) and Oct-4 (Santa Cruz)]. Following incubation,
cells were washed in PBS and then treated with 3% BSA for
20 min before being incubated for 1 hr at 37uC with the
appropriate AlexaFlor488-conjugated secondary antibody (Molec-
ular Probes; 1:100) and TOTO-3 (Invitrogen) to stain the nucleus.
Cells were given a final wash in PBS, then mounted on slides using
9:1 PBS: glycerol and sealed with nail polish. Slides were analyzed
using a Zeiss 510 confocal microscope with a 488 nm filter, and
images prepared with Zeiss LSM image browsing software.
Flow Cytometry
Cells obtained from at least 3 independent experiments were
stained using the primary antibodies described above. Primary
antibodies were directly conjugated to Alexa Fluor 488 using
Zenon conjugation kits (Invitrogen) following manufacturer’s
instructions. The single cell suspension was subjected to fluores-
cence-activated cell counting using a Calibur instrument and the
CellQuest software from Becton Dickinson. Anti-mouse, goat or
rabbit secondary antibodies were used as isotype controls.
Quantitative Polymerase Chain Reaction (qPCR)
RNA was collected using Trizol (Invitrogen) and converted to
cDNA using a capacity kit (Applied Biosystems (ABI), Carlsbad,
CA). The cDNA was probed using validated Taqman primer/
probe-sets for murine GFAP, b-catenin, GATA-6, SSEA-1,
Brachyury, SMA, MyoD, NF-68, Ezrin, Radixin, Moesin and
Oct-4 on an ABI 7900HT using 18S as the internal control and
the ddCT method included within the ABI software to analyze
results.
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